# Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

> **NCT04833257** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 63 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** GP combine with Tislelizumab neoadjuvant therapy+CCRT

## Key facts

- **NCT ID:** NCT04833257
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833257, "Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04833257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*